Abstracts tagged "autoantibodies"

Abstract Number: 1210 • 2015 ACR/ARHP Annual Meeting
Genetic, Environmental, and Serologic Risk Factors for Inflammatory Joint Signs Among First-Degree Relatives without Rheumatoid Arthritis in a Prospective Cohort
Jeffrey A. Sparks¹, Shun-Chiao Chang², Kevin D. Deane³, Ryan W. Gan⁴, Kristen Demoruelle³, Marie L. Feser³, LauraKay Moss³, Jane H. Buckner⁵, Richard M. Keating⁶, Karen H. Costenbader⁷, Peter K. Gregersen⁸, Michael H. Weisman⁹, Ted R. Mikuls¹⁰, James R. O'Dell¹⁰, V. Michael Holers³, Jill M. Norris⁴ and Elizabeth W. Karlson², ¹Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴Epidemiology, Colorado School of Public Health, Aurora, CO, ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶Division of Rheumatology, Scripps Health, La Jolla, CA, ⁷Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁸Feinstein Insititute for Medical Research, Manhasset, NY, ⁹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Family history of RA in a first-degree relative increases RA risk 4-fold. Determining risk factors for inflammatory joint signs (IJS) in this high risk…
Abstract Number: 2076 • 2015 ACR/ARHP Annual Meeting
Development of Lupus Nephritis: Preclinical Evaluation of Patients Who Subsequently Develop Systemic Lupus Erythematosus Demonstrate Elevation of Select Soluble Mediators Prior to and at Disease Classification in Patients with Nephritis
Melissa E. Munroe¹, Jourdan R. Anderson¹, Julie M. Robertson¹, Timothy B. Niewold², George C. Tsokos³, Michael P. Keith⁴, Joan T. Merrill⁵, Jill P. Buyon⁶, John B. Harley⁷ and Judith A. James⁸, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴Walter Reed National Military Medical Center, Bethesda, MD, ⁵Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁷Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Arthritis and Clinical Immunology, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: SLE is a heterogeneous autoimmune disease marked by immune dysregulation and a spectrum of pathogenic autoantibodies. Why some patients have only moderate symptoms and…
Abstract Number: 623 • 2015 ACR/ARHP Annual Meeting
Seronegative Sjögren’s Syndrome Is Characterized By a Lower Prevalence of B-Cell Related Clinical Manifestations and a Lower Biologic Systemic Activity
Luca Quartuccio¹, Chiara Baldini^2,3,4, Elena Bartoloni Bocci⁵, Roberta Priori⁶, Francesco Carubbi⁷, Laura Corazza¹, Alessia Alunno⁸, Serena Colafrancesco⁶, Nicoletta Luciano², Roberto Gerli⁹, Roberto Giacomelli¹⁰, Guido Valesini¹¹, Stefano Bombardieri¹² and Salvatore De Vita^13,14, ¹S. Maria della Misericordia, University of Udine, Italy, Udine, Italy, ²Internal Medicine, University of Pisa, Pisa, Italy, ³University of Pisa, Rheumatology Unit, Pisa, Italy, ⁴Department of Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁵Rheumatology Unit, Department of Medicine, University of Perugia, Pila, Italy, ⁶Rheumatology Unit, Sapienza University of Rome, Rome, Italy, ⁷Rheumatology Clinic, University of L'Aquila, L'Aquila, Italy, ⁸Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ⁹Rheumatology Clinic, University of Perugia, Perugia, Italy, ¹⁰University of L'Aquila, L'Aquila, Italy, ¹¹Internal Medicine and Medical Specialties Department, Policlinico Umberto I, La Sapienza University of Rome, Roma, Italy, ¹²Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ¹³Santa Maria della Misericordia Hospital, University of Udine, Udine, Italy, ¹⁴Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy
Background/Purpose: The American-European Consensus Group (AECG) Criteria (1) for Sjögren's syndrome (SS) require the presence of at least one of the following two conditions: the…
Abstract Number: 1363 • 2015 ACR/ARHP Annual Meeting
Changes in Cyclooxygenase-2’s Expression, and PGE2’s and 6-Keto-PGF1α Levels in the Presence of the Muscarinic Acethylcholine Receptor Antibody in Primary Sjogren Syndrome
Micaela Ana Cosatti¹, Silvia Reina², Cecilia N. Pisoni³, Alicia Eimon⁴, Sabrina Ganzinelli² and Enri Borda², ¹Section Rheumatology and Immunology, CEMIC, CABA, Argentina, ²Pharmacology Unit, School of Dentistry, University of Buenos Aires, Buenos Aires, Argentina; National Research Council of Argentina (CONICET), Buenos Aires, Argentina, ³Lupus Research Unit, The Rayne Institute, St Thomas' Hospital and Kings College London, London, United Kingdom, ⁴CEMIC, Buenos Aires, Argentina
Background/Purpose: to assess the inflammatory process provoked by the M3 muscarinic acetylcholine receptor antibody from primary Sjogren Syndrome (pSS) patient’s sera in rat submandibular gland…
Abstract Number: 2366 • 2015 ACR/ARHP Annual Meeting
The Anti-MDA5 Autoantibody Phenotype: Defining Clinical, Biochemical and Radiological Features Suggestive of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease
Sabrina Hoa¹, Yves Troyanov¹, Marvin J. Fritzler², Ira N. Targoff³, Anne-Marie Mansour¹, Eric Rich¹, Hind Boudabbouz¹, Josiane Bourré-Tessier¹, Sandra Chartrand¹, Marianne Landry¹, Martin Albert¹ and Jean-Luc Senécal¹, ¹Université de Montréal, Montreal, QC, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Veterans Affairs Medical Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Anti-MDA5 autoantibody associated syndrome is a novel entity within the spectrum of autoimmune myositis. It has been described as a clinical mimic of the…
Abstract Number: 740 • 2015 ACR/ARHP Annual Meeting
The Prevalence of Anti-DFS70 Antibodies in an International Inception Cohort of Systemic Lupus Erythematosus
May Choi¹, John G. Hanly², Murray Urowitz^3,4, Juanita Romero-Diaz⁵, Caroline Gordon⁶, Sang-Cheol Bae⁷, Sasha Bernatsky⁸, Daniel J Wallace⁹, Joan T. Merrill¹⁰, David A. Isenberg¹¹, Anisur Rahman¹², Ellen M. Ginzler¹³, Paul R. Fortin¹⁴, Dafna Gladman¹⁵, Jorge Sanchez-Guerrero¹⁶, Michelle Petri¹⁷, Ian N. Bruce¹⁸, Mary Anne Dooley¹⁹, Rosalind Ramsey-Goldman²⁰, Cynthia Aranow²¹, Graciela S. Alarcon²², Kristján Steinsson²³, Ola Nived²⁴, Gunnar K. Sturfelt²⁵, Susan Manzi²⁶, Munther Khamashta²⁷, Ronald F. van Vollenhoven²⁸, Asad Zoma²⁹, Guillermo Ruiz-Irastorza³⁰, S. Sam Lim³¹, Thomas Stoll³², Murat Inanc³³, Kenneth C. Kalunian³⁴, Diane L. Kamen³⁵, Peter Maddison³⁶, Christine A. Peschken³⁷, Søren Jacobsen³⁸, Anca Askanase³⁹, Jill P. Buyon⁴⁰, W. Winn Chatham⁴¹, Manuel Ramos-Casals⁴², Yvan St. Pierre⁴³, Ann E. Clarke⁴⁴ and Marvin J. Fritzler¹, ¹Medicine, University of Calgary, Calgary, AB, Canada, ²Rheumatology, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ³Rheumatology, TWH, Toronto, ON, Canada, ⁴Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ⁶Rheumatology (East Wing), Medical School, Birmingham, United Kingdom, ⁷Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁸Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, ⁹Cedars-Sinai Medical Center, West Hollywood, CA, ¹⁰Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ¹²Centre for Rheumatology Research, U College of London, London, United Kingdom, ¹³Medicine/Box 42, SUNY-Downstate, Brooklyn, NY, ¹⁴Rheumatology, University of Laval, Quebec, QC, Canada, ¹⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹⁶Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ¹⁷Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, ¹⁸Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ¹⁹UNC Kidney Centre, Chapel Hill, NC, ²⁰Northwestern University Feinberg School of Medicine, Chicago, IL, ²¹Feinstein Institute for Medical Research, Mahasset, NY, ²²Medicine, University of Alabama at Birmingham, Birmingham, AL, ²³Rheumatology, Univ. Hospital, Reykjavik, Iceland, ²⁴Rheumatology, Inst of Clinical sciences, Lund, Sweden, ²⁵Department of Rheumatology, Univ Hospital Lund, Lund, Sweden, ²⁶Rheumatology, Allegheny Health Network, Pittsburgh, PA, ²⁷Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ²⁸Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²⁹Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, ³⁰Universidad del Pais Vasco, Servicio de Medicina Interna, Hospital de Cruces, Bizkaia, Spain, ³¹Emory University School of Medicine, Atlanta, GA, ³²Abteilung Rheumatologie/Rehab, Kantonsspital Schaffhausen, Schaffhausen, Switzerland, ³³Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³⁴Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ³⁵Medicine, Medical University of South Carolina, Charleston, SC, ³⁶School of Sport, Health and Exercise Sciences, Bangor University, George Building, Bangor, Gwynedd, LL57 2PZ, UK., Bangor, United Kingdom, ³⁷Rheumatology, Univ of Manitoba, Winnipeg, MB, Canada, ³⁸Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ³⁹Columbia University College of Physicians & Surgeons, New York, NY, ⁴⁰Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴¹Medicine/Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴²Department of Autoimmune Diseases, CELLEX-IDIBAPS, Hospital Clínic, Barcelona, Barcelona, Spain, ⁴³Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴⁴Immunology/Epidemiology, Montreal General Hospital, Montreal, QC, Canada
Background/Purpose: Autoantibodies to the nuclear autoantigen dense fine speckles 70 (DFS70) are associated with a new paradigm whereby when they are found in isolation (monospecific…
Abstract Number: 1463 • 2015 ACR/ARHP Annual Meeting
Anti-Cyclic Citrullinated Peptide Antibody Subclass Phenotypes in Polyarticular Juvenile Idiopathic Arthritis
Hannah Peckham¹, Lauren Bourke^2,3, Anna Radziszewska⁴, Maria Leandro⁵, Debajit Sen², Geraldine Cambridge⁶ and Yiannis Ioannou^7,8, ¹Adolescent Centre for Rheumatology Research, University College London, London, United Kingdom, ²Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ³Centre for Rheumatology Research, University College London, London, United Kingdom, ⁴The Rayne Institute, Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, ⁵Centre for Rheumatology, University College London, London, United Kingdom, ⁶Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁷Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, ⁸Centre for Rheumatology Research, University College Hospital London, London, United Kingdom
Background/Purpose: Raised levels of Rheumatoid Factor (RhF) and antibodies to citrullinated proteins (ACPA), detected in the clinic using combinations of cyclic citrullinated peptides (CCP), are…
Abstract Number: 2368 • 2015 ACR/ARHP Annual Meeting
Myositis Specific-Autoantibodies: Predictors of Short-Term Good Outcome in Rituximab Treated-Refractory Idiopathic Inflammatory Myopathies
Fernando Henrique Carlos de Souza¹, Renata Miossi², Julio C. B. Moraes¹, Karina Bonfiglioli¹, Eloisa Bonfá¹ and Samuel Katsuyuki Shinjo¹, ¹Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
Background/Purpose: The treatment of idiopathic inflammatory myopathies (IIM) is challenging, complicated by its rarity and heterogeneity. Currently few studies have suggested the efficacy of RTX…
Abstract Number: 788 • 2015 ACR/ARHP Annual Meeting
Identification of Molecular Biomarkers to Distinguish Systemic Lupus Erythematosus with Skin Involvement from Discoid Lupus Erythematosus and Subacute Cutaneous Erythematosus: Provisional Results from Cross-Sectional Studies
Matteo Cesaroni¹, Jarrat Jordan¹, Jessica Schreiter¹, Marc Chevrier¹, Grace Wang², Cesar Calderon³, Alexa Piantone², Ian Gourley⁴, Stanley Cohen⁵, Scott Fretzin⁶, Anna Wozniacka⁷, Victoria P. Werth⁸ and Jacqueline Benson¹, ¹Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA, ²Janssen Research and Development, Spring House, PA, ³37 Derwen Dr., Janssen Research and Development, Havertown, PA, ⁴1329 Anthony Wayne drive, Janssen Research and Development, Wayne, PA, ⁵Metroplex Clinical Research Center, LLC, Dallas, TX, ⁶Dawes Fretzin Clinical Research Group, LLCC, Indianapolis, IN, ⁷Medical University of Lodz, Lodz, Poland, ⁸Philadelphia VA Medical Center, Philadelphia, PA
Background/Purpose: Sub-classification of Lupus Erythematosus (LE) patients is largely based on defined clinical criteria while biological factors associating with or contributing to these clinical features…
Abstract Number: 1625 • 2015 ACR/ARHP Annual Meeting
Role of Macrophages in the Cardiovascular Disease Associated to Rheumatoid Arthritis: Effects of ANTI-CCPS in the Phenotypic Switching and the Insulin Signalling
Patricia Ruiz-Limon, Yolanda Jiménez Gómez, Carlos Perez-Sanchez, MariCarmen Abalos-Aguilera, M.Ángeles Aguirre Zamorano, Jerusalem Calvo-Gutierrez, Rafaela Ortega, Eduardo Collantes-Estévez, Alejandro Escudero-Contreras, Chary Lopez-Pedrera and Nuria Barbarroja, IMIBIC-Reina Sofia University Hospital, Rheumatology Unit, Cordoba, Spain
Background/Purpose: Macrophages play a key role in the pathogenesis of the rheumatoid arthritis (RA). Under certain stimulus conditions these cells are able to switch their…
Abstract Number: 2370 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics of Anti-MDA5 (+) Dermatomyositis Patients in North America
Siamak Moghadam-Kia¹, Chester V. Oddis², Shinji Sato³, Masataka Kuwana⁴ and Rohit Aggarwal⁵, ¹Medicine-Myositis Center and Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Rheumatology, Tokai University School of Medicine, Isehara, Japan, ⁴Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ⁵Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Clinically amyopathic dermatomyositis (CADM) patients have the classic rash (es) of DM but no objective proximal muscle weakness. Asian studies report a unique clinical phenotype in anti-MDA5…
Abstract Number: 810 • 2015 ACR/ARHP Annual Meeting
Human Parvovirus B19 Nonstructural Protein 1 (NS1) Helicase Breaks Tolerance to Self dsDNA: A Model for Viral Induction of Autoimmunity
Heidi Pirttinen¹, Kanoktip Puttaraksa¹, Robert J. Lagier², Stanley J. Naides³ and Leona Gilbert¹, ¹Department of Biological and Environmental Science, University of Jyväskylä, Jyväskylä, Finland, ²Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, ³Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA
Background/Purpose: B19 virus (B19V) is common, infects all ages, and is associated with various clinical syndromes including SLE-like autoimmunity. We previously demonstrated that B19 NS1,…
Abstract Number: 1750 • 2015 ACR/ARHP Annual Meeting
Identification of Autoantibody-Inducing CD4 T Cell (aiCD4 T cell) That Causes Systemic Lupus Erythematosus (SLE) As DOCK8+ CD4 T Cell: Proof of Concept of Self-Organized Criticality Theory
Shunichi Shiozawa¹, Yumi Miyazaki², Kazuko Shiozawa³ and Ken Tsumiyama², ¹Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan, ²Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan, ³Rheumatic Diseases Center, Konan Kakogawa Hospital, Kakogawa, Japan
Background/Purpose: We have shown that repeated immunization with antigen causes systemic autoimmunity in mice otherwise not prone to spontaneous autoimmune diseases. Overstimulation of CD4 T…
Abstract Number: 2461 • 2015 ACR/ARHP Annual Meeting
Identification of Target Antigens for Anti-Endothelial Cell Antibodies in Patients with Pediatric Rheumatic Diseases Using Proteomics
Rie Karasawa¹, Mayumi Tamaki¹, Yanmin Chen², Kaiyu Jiang², Kazuo Yudoh¹ and James Jarvis², ¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, ²Pediatrics, The University at Buffalo, Buffalo, NY
Background/Purpose: Juvenile dermatomyositis (JDM), the most common inflammatory myopathy of childhood, is a rare systemic autoimmune vasculopathy. Juvenile idiopathic arthritis (JIA), the most common pediatric…
Abstract Number: 864 • 2015 ACR/ARHP Annual Meeting
Anticytokine Autoantibody Profiling in Five Types of Systemic Vasculitis
Sarthak Gupta^1,2, Seema K. Patel², Mary Blake², Massimo G. Gadina², Wanxia L. Tsai², Simon Carette³, David Cuthbertson⁴, Gary S. Hoffman⁵, Nader A. Khalidi⁶, Curry L. Koening⁷, Carol A. Langford⁵, Carol A. McAlear⁸, Larry W. Moreland⁹, Paul A. Monach¹⁰, Christian Pagnoux³, Philip Seo¹¹, Ulrich Specks¹², Antoine G. Sreih¹³, Steven R. Ytterberg¹⁴, Sarah K. Browne^1,15, Steven M. Holland¹, Mariana J. Kaplan², Peter A. Merkel¹⁶, Peter C. Grayson² and Vasculitis Clinical Research Consortium, ¹Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁵Rheumatology, Cleveland Clinic, Cleveland, OH, ⁶Division of Rheumatology, St. Joseph’s Health Care, McMaster University, Hamilton, ON, Canada, ⁷Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁸Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁹Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹⁰Rheumatology, Boston University School of Medicine, Boston, MA, ¹¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹²Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, MN, ¹³Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁴Rheumatology Division, Mayo Clinic, Rochester, MN, ¹⁵Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, ¹⁶Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Anticytokine autoantibodies (ACAs) are pathogenic in many hematologic, pulmonary and infectious diseases. Evaluation in autoimmune diseases, including systemic lupus erythematosus (SLE), shows that ACAs…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.